Allecra
Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company dedicated to developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Their mission is to contribute to the global effort to fight antimicrobial resistance by creating effective treatments that address this critical healthcare challenge. The company is advancing a lead product, cefepime/enmetazobactam, which has demonstrated superiority over standard care in clinical trials for complicated urinary tract infections, and is preparing for regulatory submissions for marketing approval in the U.S. and EU. Supported by significant patent protection and a team of experienced management and advisory board members, Allecra aims to provide innovative solutions to address the growing crisis of antibiotic resistance.
Industries
Nr. of Employees
small (1-50)
Allecra
Patents
Products
Fourth‑generation cephalosporin plus extended‑spectrum β‑lactamase inhibitor combination (antibiotic therapy)
Clinical-stage intravenous antibiotic combination comprising a fourth‑generation cephalosporin paired with a novel extended‑spectrum β‑lactamase inhibitor, developed for treatment of complicated urinary tract infections and intended to provide activity against ESBL-producing Enterobacterales and other resistant Gram-negative pathogens.
Fourth‑generation cephalosporin plus extended‑spectrum β‑lactamase inhibitor combination (antibiotic therapy)
Clinical-stage intravenous antibiotic combination comprising a fourth‑generation cephalosporin paired with a novel extended‑spectrum β‑lactamase inhibitor, developed for treatment of complicated urinary tract infections and intended to provide activity against ESBL-producing Enterobacterales and other resistant Gram-negative pathogens.
Services
Engagement in out-licensing, territorial licensing and supply agreements for clinical-stage antibiotic candidates and coordination of commercialization partnerships.
Engagement in out-licensing, territorial licensing and supply agreements for clinical-stage antibiotic candidates and coordination of commercialization partnerships.
Expertise Areas
- Clinical trial management for anti-infectives
- Antibacterial drug discovery and development
- Pharmacokinetics / pharmacodynamics (PK/PD) and dose optimization
- Microbiology and antimicrobial susceptibility testing
Key Technologies
- Broth microdilution MIC testing
- Disk diffusion susceptibility testing
- Monte Carlo simulation for PK/PD
- Murine infection models (thigh, pneumonia, septicemia)